HC Wainwright & Co. Reiterates Buy on Nektar Therapeutics, Maintains $185 Price Target
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsReiterationPrice Target
HC Wainwright & Co. analyst Arthur He reiterates Nektar Therapeutics (NASDAQ:NKTR) with a Buy and maintains $185 price target.
HC Wainwright & Co. analyst Arthur He reiterates Nektar Therapeutics (NASDAQ:NKTR) with a Buy and maintains $185 price target.